# ALX Oncology Holdings Inc: financial statements, quarterly

ALXO · Nasdaq · CIK 1810182 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alxo.md) · [Financials](/companies/alxo/financials.md) · [Filings](/companies/alxo/filings.md) · [Insiders](/companies/alxo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alxo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [45.8](/filings/0000950170-24-123290.md) | [41.8 d](/filings/0001193125-26-098454.md) | [31.7](/filings/0000950170-25-066894.md) | [34.7](/filings/0000950170-25-107303.md) | [26.5](/filings/0001193125-25-272281.md) | [23.5 d](/filings/0001193125-26-098454.md) | [23.9](/filings/0001193125-26-213399.md) | [18.0](/filings/0001193125-26-337920.md) | [17.4](/filings/0001193125-25-272281.md) | [17.6 d](/filings/0001193125-26-098454.md) | [13.6](/filings/0001193125-26-213399.md) | [13.1](/filings/0001193125-26-337920.md) |
| Operating income | $m | [(53.3)](/filings/0000950170-24-123290.md) | [(48.0) d](/filings/0001193125-26-098454.md) | [(37.8)](/filings/0000950170-25-066894.md) | [(41.5)](/filings/0000950170-25-107303.md) | [(32.6)](/filings/0001193125-25-272281.md) | [(30.6) d](/filings/0001193125-26-098454.md) | [(31.8)](/filings/0001193125-26-213399.md) | [(26.6)](/filings/0001193125-26-337920.md) | [(22.5)](/filings/0001193125-25-272281.md) | [(23.0) d](/filings/0001193125-26-098454.md) | [(19.0)](/filings/0001193125-26-213399.md) | [(18.0)](/filings/0001193125-26-337920.md) |
| Interest expense | $m | [0.4](/filings/0000950170-24-123290.md) | [0.4 d](/filings/0001193125-26-098454.md) | [0.4](/filings/0000950170-25-066894.md) | [0.4](/filings/0000950170-25-107303.md) | [0.4](/filings/0001193125-25-272281.md) | [0.4 d](/filings/0001193125-26-098454.md) | [0.4](/filings/0001193125-26-213399.md) | [0.4](/filings/0001193125-26-337920.md) | [0.4](/filings/0001193125-25-272281.md) | [0.4 d](/filings/0001193125-26-098454.md) | [0.3](/filings/0001193125-26-213399.md) | [0.3](/filings/0001193125-26-337920.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(51.0)](/filings/0000950170-24-123290.md) | [(45.5) d](/filings/0001193125-26-098454.md) | [(35.6)](/filings/0001193125-25-272281.md) | [(39.4)](/filings/0001193125-25-272281.md) | [(30.7)](/filings/0001193125-25-272281.md) | [(29.2) d](/filings/0001193125-26-098454.md) | [(30.8)](/filings/0001193125-26-337920.md) | [(25.9)](/filings/0001193125-26-337920.md) | [(22.1)](/filings/0001193125-25-272281.md) | [(22.8) d](/filings/0001193125-26-098454.md) | [(17.9)](/filings/0001193125-26-337920.md) | [(18.0)](/filings/0001193125-26-337920.md) |
| Diluted EPS | $ per share | [(1.24)](/filings/0000950170-24-123290.md) | not reported | [(0.71)](/filings/0000950170-25-066894.md) | [(0.76)](/filings/0000950170-25-107303.md) | [(0.58)](/filings/0001193125-25-272281.md) | not reported | [(0.58)](/filings/0001193125-26-213399.md) | [(0.49)](/filings/0001193125-26-337920.md) | [(0.41)](/filings/0001193125-25-272281.md) | not reported | [(0.17)](/filings/0001193125-26-213399.md) | [(0.13)](/filings/0001193125-26-337920.md) |
| Basic EPS | $ per share | [(1.24)](/filings/0000950170-24-123290.md) | not reported | [(0.71)](/filings/0000950170-25-066894.md) | [(0.76)](/filings/0000950170-25-107303.md) | [(0.58)](/filings/0001193125-25-272281.md) | not reported | [(0.58)](/filings/0001193125-26-213399.md) | [(0.49)](/filings/0001193125-26-337920.md) | [(0.41)](/filings/0001193125-25-272281.md) | not reported | [(0.17)](/filings/0001193125-26-213399.md) | [(0.13)](/filings/0001193125-26-337920.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.6](/filings/0000950170-24-123290.md) | [22.4](/filings/0001193125-26-098454.md) | [14.0](/filings/0000950170-25-066894.md) | [15.5](/filings/0000950170-25-107303.md) | [16.1](/filings/0001193125-25-272281.md) | [17.6](/filings/0001193125-26-098454.md) | [20.6](/filings/0001193125-26-213399.md) | [19.3](/filings/0001193125-26-337920.md) | [23.4](/filings/0001193125-25-272281.md) | [16.4](/filings/0001193125-26-337920.md) | [32.3](/filings/0001193125-26-213399.md) | [22.7](/filings/0001193125-26-337920.md) |
| Current assets | $m | [199](/filings/0000950170-23-062929.md) | [189](/filings/0000950170-25-034761.md) | [168](/filings/0000950170-24-056953.md) | [169](/filings/0000950170-24-095391.md) | [156](/filings/0000950170-24-123290.md) | [134](/filings/0001193125-26-098454.md) | [103](/filings/0000950170-25-066894.md) | [85.3](/filings/0000950170-25-107303.md) | [66.5](/filings/0001193125-25-272281.md) | [50.7](/filings/0001193125-26-337920.md) | [146](/filings/0001193125-26-213399.md) | [143](/filings/0001193125-26-337920.md) |
| Total assets | $m | [220](/filings/0000950170-23-062929.md) | [243](/filings/0000950170-25-034761.md) | [213](/filings/0000950170-24-056953.md) | [215](/filings/0000950170-24-095391.md) | [186](/filings/0000950170-24-123290.md) | [148](/filings/0001193125-26-098454.md) | [121](/filings/0000950170-25-066894.md) | [95.3](/filings/0000950170-25-107303.md) | [82.7](/filings/0001193125-25-272281.md) | [59.0](/filings/0001193125-26-337920.md) | [178](/filings/0001193125-26-213399.md) | [161](/filings/0001193125-26-337920.md) |
| Current liabilities | $m | [35.1](/filings/0000950170-23-062929.md) | [36.0](/filings/0000950170-25-034761.md) | [32.2](/filings/0000950170-24-056953.md) | [38.4](/filings/0000950170-24-095391.md) | [32.3](/filings/0000950170-24-123290.md) | [18.5](/filings/0001193125-26-098454.md) | [18.7](/filings/0000950170-25-066894.md) | [18.8](/filings/0000950170-25-107303.md) | [27.7](/filings/0001193125-25-272281.md) | [24.6](/filings/0001193125-26-337920.md) | [20.2](/filings/0001193125-26-213399.md) | [14.8](/filings/0001193125-26-337920.md) |
| Total liabilities | $m | [51.4](/filings/0000950170-23-062929.md) | [52.8](/filings/0000950170-25-034761.md) | [48.5](/filings/0000950170-24-056953.md) | [55.3](/filings/0000950170-24-095391.md) | [48.9](/filings/0000950170-24-123290.md) | [34.2](/filings/0001193125-26-098454.md) | [32.6](/filings/0000950170-25-066894.md) | [30.9](/filings/0000950170-25-107303.md) | [37.9](/filings/0001193125-25-272281.md) | [33.1](/filings/0001193125-26-337920.md) | [27.0](/filings/0001193125-26-213399.md) | [24.6](/filings/0001193125-26-337920.md) |
| Long-term debt | $m | [9.6](/filings/0000950170-23-062929.md) | [9.6](/filings/0000950170-25-034761.md) | [9.7](/filings/0000950170-24-056953.md) | [9.8](/filings/0000950170-24-095391.md) | [9.8](/filings/0000950170-24-123290.md) | [9.5](/filings/0001193125-26-098454.md) | [8.2](/filings/0000950170-25-066894.md) | [7.0](/filings/0000950170-25-107303.md) | [5.8](/filings/0001193125-25-272281.md) | [4.5](/filings/0001193125-26-337920.md) | [3.3](/filings/0001193125-26-213399.md) | [9.7](/filings/0001193125-26-337920.md) |
| Current portion of debt | $m | [0.0](/filings/0000950170-23-062929.md) | [0.0](/filings/0000950170-24-027955.md) | [0.0](/filings/0000950170-24-056953.md) | [0.0](/filings/0000950170-24-095391.md) | [0.0](/filings/0000950170-24-123290.md) | [0.4](/filings/0001193125-26-098454.md) | [1.7](/filings/0000950170-25-066894.md) | [3.0](/filings/0000950170-25-107303.md) | [4.3](/filings/0001193125-25-272281.md) | [5.2](/filings/0001193125-26-337920.md) | [5.2](/filings/0001193125-26-213399.md) | [0.0](/filings/0001193125-26-337920.md) |
| Shareholders' equity | $m | [169](/filings/0000950170-24-123290.md) | [190](/filings/0001193125-26-098454.md) | [164](/filings/0001193125-25-272281.md) | [159](/filings/0001193125-25-272281.md) | [137](/filings/0001193125-25-272281.md) | [114](/filings/0001193125-26-337920.md) | [88.3](/filings/0001193125-26-337920.md) | [64.4](/filings/0001193125-26-337920.md) | [44.8](/filings/0001193125-25-272281.md) | [26.0](/filings/0001193125-26-337920.md) | [151](/filings/0001193125-26-337920.md) | [136](/filings/0001193125-26-337920.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(31.2) d](/filings/0000950170-24-123290.md) | [(39.7) d](/filings/0001193125-26-098454.md) | [(37.9)](/filings/0000950170-25-066894.md) | [(26.6) d](/filings/0000950170-25-107303.md) | [(25.4) d](/filings/0001193125-25-272281.md) | [(32.0) d](/filings/0001193125-26-098454.md) | [(24.7)](/filings/0001193125-26-213399.md) | [(23.4) d](/filings/0001193125-26-337920.md) | [(17.1) d](/filings/0001193125-25-272281.md) | [(19.0) d](/filings/0001193125-26-098454.md) | [(18.6)](/filings/0001193125-26-213399.md) | [(16.1) d](/filings/0001193125-26-337920.md) |
| Capital expenditure | $m | [(1.3) d](/filings/0000950170-24-123290.md) | [0.1 d](/filings/0001193125-26-098454.md) | [0.1](/filings/0000950170-25-066894.md) | [0.1 d](/filings/0000950170-25-107303.md) | [0.1 d](/filings/0001193125-25-272281.md) | [0.1 d](/filings/0001193125-26-098454.md) | [0.1](/filings/0001193125-26-213399.md) | [0.0 d](/filings/0001193125-26-337920.md) | [0.1 d](/filings/0001193125-25-272281.md) | [0.0 d](/filings/0001193125-26-098454.md) | [0.1](/filings/0001193125-26-213399.md) | [0.0 d](/filings/0001193125-26-337920.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.7](/filings/0000950170-23-062929.md) | [40.9](/filings/0000950170-24-056953.md) | [40.9](/filings/0000950170-24-095391.md) | [41.1](/filings/0000950170-24-123290.md) | [50.1](/filings/0000950170-25-066894.md) | [51.8](/filings/0000950170-25-107303.md) | [52.7](/filings/0001193125-25-272281.md) | [53.4](/filings/0001193125-26-213399.md) | [53.4](/filings/0001193125-26-337920.md) | [53.6](/filings/0001193125-25-272281.md) | [105](/filings/0001193125-26-213399.md) | [136](/filings/0001193125-26-337920.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 138,276,997 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337920.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.